The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia

There are currently no regulatory approved pharmacological treatments for cognitive impairment associated with schizophrenia (CIAS). One possibility is that trial methodology itself is hindering their development. Emerging evidence suggests that patients with schizophrenia may show limited benefit f...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotter, Jack, Barnett, Jennifer H., Granger, Kiri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743013/
https://www.ncbi.nlm.nih.gov/pubmed/31551837
http://dx.doi.org/10.3389/fpsyt.2019.00648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743013/
https://www.ncbi.nlm.nih.gov/pubmed/31551837
http://dx.doi.org/10.3389/fpsyt.2019.00648

Ejemplares similares